IRL201805 / Revolo Biotherap - LARVOL DELTA

The Biologic IRL201805 Alters Immune Tolerance Leading to Prolonged Pharmacodynamics and Efficacy in Rheumatoid Arthritis Patients. (PubMed, Int J Mol Sci) - "In secondary co-culture, pre-infusion PBMCs cultured 1:1 with autologous PBMCs, isolated at later time-points during the trial, showed significantly inhibited IL-6 and IL-1β production upon anti-CD3/CD28 stimulation demonstrating IRL201805 alters the function of immune cells leading to prolonged pharmacodynamics confirmed by biomarker differences. IRL201805 may be the first of a new class of biologic drug providing long-term drug-free therapy in RA."

Biomarker • Clinical • IO biomarker • Journal • PK/PD data • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CD4 • CTLA4 • ENTPD1 • HSPA5 • IFNG • IL1B • IL6 • IL7R

Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients (ACR Convergence 2023) - "Our finding suggest that IRL201805 inhibits osteoclast differentiation via modulation of RANK/RANKL signaling. Notably, there is an impact on metabolic pathways such as V-ATPases, which are critical for bone resorption. This is particulary revelant, as antiresorptive drugs that inhibit V-ATPase activity in osteoclasts have become an area of development."

Clinical • Immunology • Inflammatory Arthritis • Orthopedics • Rheumatoid Arthritis • Rheumatology • CD14 • CSF1 • HSPA5 • TNFSF11

Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors (ACR Convergence 2023) - "Our data suggests that IRL201805 selectively target transcriptional changes in RA and not healthy monocytes. Notably, IRL201805 downregulates transcripts that are upregulated in RA whilst simultaneously upregulating transcripts that are downregulated in RA. Combined this suggests that IRL201805 has the capacity to 'reset' a number of cell-cell and metabolic linked inflammatory pathways in disease-state cells."

Clinical • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CD14 • CSF1 • HSPA5

Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference (GlobeNewswire) - "Preclinical and clinical studies to date have demonstrated that ‘1805 interacts directly with monocytes, cells which play a key role in the initiation of inflammation and bone erosion in RA patients....Gene expression data from RA-derived monocytes and those from healthy donors indicate that ‘1805 upregulates the expression of genes that are downregulated in RA while simultaneously downregulating the expression of genes that are upregulated in RA, such as those involved in inflammatory pathways; Evaluation of gene expression showed that exposure of pre-osteoclasts to ‘1805 influenced the expression of multiple other genes involved in osteoclast differentiation."

Preclinical • Immunology • Rheumatoid Arthritis

Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit (GlobeNewswire) - "Revolo Biotherapeutics...announced new pre-clinical and ex-vivo data in an oral presentation at the 5th Treg Directed Therapies Summit, showcasing the ability of its immune-resetting drug candidate ‘1805 to alter the T regulatory cell (Treg) phenotype, gene expression and inflammation in human gut tissue with inflammatory bowel disease (IBD) as well as selectively alter transcripts in macrophages harvested from rheumatoid arthritis (RA) subjects....Enhanced generation of double positive CD69+/CD39+ FoxP3 Tregs in the inflamed lamina propria of gut biopsies from IBD patients following treatment with ‘1805 while non-inflamed tissue biopsies did not....Following treatment with ‘1805, macrophages harvested from RA subjects experienced a selective reduction in pro-inflammatory gene transcripts in comparison to healthy controls which showed very little alteration in transcripts."

Preclinical • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis